ASCO 2019 | FORTE trial: updated efficacy analysis by risk status

Francesca Gay, University of Torino, Torino, IT, presents a risk analysis update from the FORTE trial of carfilzomib + lenalidomide + dexamethasone (KRd) with, or without, transplantation in patients with newly diagnosed multiple myeloma (NDMM). This interview was conducted during the 2019 ASCO meeting in Chicago, US. This analysis showed that KRd both with, and without, transplant was highly effective at inducing responses and minimal residual disease (MRD) negativity. Approximately 50% of high-risk patients treated with KRd (with or without) transplant achieved MRD negativity. Patients who were transplanted, achieved a higher rate of sustained MRD negativity at 1 year. Additionally, transplant was of more benefit in patients with high-risk disease, as it led to a reduced risk of early relapse (within 18 months from start of therapy).